THE US Food and Drug
Administration has approved
marketing of the first medical
device based on brain function
to help assess attention-deficit/
hyperactivity disorder (ADHD) in
children and adolescents 6 to 17
years old.
The device, the Neuropsychiatric
EEG-Based Assessment Aid
(NEBA) System, is based on
electroencephalogram (EEG)
technology, which records the
frequency and type of electrical
impulses given off by neurons.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jul 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.